Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
Sanofi (SNY) Q4 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Houman Ashrafian - Executive Vice President, Head of Research and Development Conference Call Participants Luisa Hector - Berenberg Graham Parry - BofA Seamus Fernandez - Guggenheim Peter Welford - Jefferies Jo Walton - UBS Richard Vosser - JPMorgan Florent Cespedes - Bernstein Securities David Risinger - Leerink Peter Verdult - BNP Exane Emmanuel Papadakis - Deutsche Bank Eric Berrigaud - Stifel Ricardo Benevides - Santander Thomas Larsen Welcome to the Q4 and Full Year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance
Sanofi CEO Paul Hudson discusses the company's quarterly earnings results and his thoughts on the confirmation hearing of RFK Jr.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmation hearing of RFK Jr., and more.
Sanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacks
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it seeks to build investor confidence in its drug pipeline.
'The next battleground': Sanofi exploring opportunities in second generation obesity drugs
Paul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground."
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi's Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 billion, including new COPD approval. Newer drugs like Beyfortus and Altuviiio show strong growth, offsetting challenges from biosimilars and generic competition.
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
